CTRI/2021/04/032545已完成4 期
A Phase IV, Multicentre, Open Label Clinical Study to Evaluate The Safety and Efficacy of Intracameral Phenocaine Plus Injection for Anaesthesia and Mydriasis in Cataract Surgery.
Entod Pharmaceuticals Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1.Male or female subjects of age between 18 to 75 years (both inclusive).
- •2.Subjects having grade 2 to 3 Cataract shall be included.
- •3.Subjects scheduled to undergo surgery for cataract.
- •4.Endothelial cell count > 2000 cell/mm2.
- •5.Pupil diameter >= 7 mm at screening.
- •6.Subjects who are willing to sign informed consent for participation in the study and willing to adhere to all protocol procedures
排除标准
- •1.Corrected visual acuity < 0.5.
- •2.Refractive Error with a spherical equivalent > +6 or smaller - 6 D.
- •3.Elevated intraocular pressure (higher than 22 mmHg).
- •4.Current or history within two months prior to baseline of significant ocular disease, e.g., corneal denervation, corneal epithelial defects, dry eye syndrome, ocular trauma to the operative eye, corneal edema, proliferative diabetic retinopathy in the operative eye or ocular infection.
- •5.In the operative eye, history of chronic or recurrent inflammatory disease, e.g., iritis, scleritis, uveitis, iridocyclitis or rubeosis iritis, lens pseudoexfoliation syndrome with glaucoma or zonular compromise of. Congenital ocular anomaly, e.g., aniridia or congenital cataract.
- •6.Iris atrophy in the operative eye.
- •7.Combined surgery
- •8.Clinically significant ocular endothelial dysfunction.
- •9.History of eye surgery apart from laser trabeculoplasty less than three months previously or extraocular surgery such as strabismus surgery.
- •10.Topical ocular medication influencing IOP (intraocular pressure) or pupil size within 3 months prior to study-start.
- •11.Nonfunctional nonoperative eye.
- •12.Any laboratory value outside the clinically accepted reference range
- •13.Subjects with Type 1 or Uncontrolled Type 2 Diabetes mellitus.
- •14.History of uncontrolled hypertension with blood pressure > 140/90 mmhg.
- •15.History of orthostatic hypotension, fainting spells or blackout.
- •16.Subjects with clinically relevant recent current or past history of severe, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal, Gastrointestinal, metabolic, autoimmune disease and other relevant systemic diseases or bleeding tendencies that would preclude the safe administration of the Investigational product.
- •17.The following concomitant medications will not be allowed:
- •- Systemic corticoid treatments and immunosuppressive treatments within 3 months before surgery;
- •-Systemic opioids and morphinic drugs within 7 days before surgery.
- •-Topical ocular treatment with mydriatic and/or anaesthetic action within 7 days before surgery;
- •-topical treatment with anti-inflammatory and antibiotic action within 1 day before surgery (except for the preoperative treatment specified in this protocol);
- •-anxiolytics and hypnotics on the day of surgery; adrenaline or any other agent with a mydriatic action in the intraocular irrigating solution on the day of surgery.
- •19.Known hypersensitivity to the active substances (tropicamide, phenylephrine, lidocaine,) or any of their excipients
- •20.Use of any drugs which might influence the results of the trial up to seven days prior to enrolment in the study or during the study
- •21.Female subjects who are pregnant or lactating or planning to become pregnant during the study period. Females who are not ready to use acceptable contraceptive methods during the course of study.
- •22.History of alcohol abuse and smoking.
- •23.Concurrent participation in another clinical trial or any investigational therapy within two months prior to signing informed consent.
研究者
相似试验
进行中（未招募）
1 期
An Open-Label, Multicenter Phase IV Study assessing safety and efficacy of ribavirin (Copegus®) as part of combination therapy with peginterferon alfa-2a (Pegasys®) in selected groups of patients with chronic viral hepatitis CEUCTR2005-003932-23-SKRoche spol. s r.o.385
进行中（未招募）
不适用
An Open-Label, Multicenter Phase IV Study assessing safety and efficacy of ribavirin (Copegus®) as part of combination therapy with peginterferon alfa-2a (Pegasys®) in selected groups of patients with chronic viral hepatitis COtevrená, multicentrická studie fáze IV hodnotící bezpecnost a úcinnost ribavirinu (Copegus®) v kombinované lécbe s peginterferonem alfa-2a (Pegasys®) u vybraných skupin pacientu s chronickou virovou hepatitidou typu C.An Open-Label, Multicenter Phase IV Study assessing safety and efficacy of ribavirin (Copegus®) as part of combination therapy with peginterferon alfa-2a (Pegasys®) in selected groups of patients with chronic viral hepatitis CEUCTR2005-003932-23-CZRoche spol. s r.o.300
进行中（未招募）
不适用
A phase IV, open-label, multi-centre trial evaluating the conversion from standard phosphate binder therapy to Fosrenol in chronic kidney disease stage 5 patients on haemodialysisHyperphosphataemia in patients with chronic kidney disease stage 5 receiving haemodialysisMedDRA version: 8.1Level: LLTClassification code 10020712Term: HyperphosphatemiaEUCTR2006-003364-64-ATShire Pharmaceutical Development Ltd760
进行中（未招募）
不适用
A phase IV, open-label, multi-centre trial evaluating the conversion from standard phosphate binder therapy to Fosrenol in chronic kidney disease stage 5 patients on haemodialysisHyperphosphataemia in patients with chronic kidney disease stage 5 receiving haemodialysisMedDRA version: 8.1Level: LLTClassification code 10020712Term: HyperphosphatemiaEUCTR2006-003364-64-FIShire Development Inc760
进行中（未招募）
1 期
A phase IV, open-label, multi-centre trial evaluating the conversion from standard phosphate binder therapy to Fosrenol in chronic kidney disease stage 5 patients on haemodialysisHyperphosphataemia in patients with chronic kidney disease stage 5 receiving haemodialysisMedDRA version: 8.1Level: LLTClassification code 10020712Term: HyperphosphatemiaEUCTR2006-003364-64-FRShire Pharmaceutical Development Ltd760